<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 15 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:"Cambria Math";
	panose-1:2 4 5 3 5 4 6 3 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:URWPalladioL-Roma;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:URWPalladioL-Bold;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:\7B49\7EBF;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@\7B49\7EBF";}
@font-face
	{font-family:Rpxr;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Rpxmi;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:0in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
a:link, span.MsoHyperlink
	{color:#0563C1;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:#954F72;
	text-decoration:underline;}
p.MsoListParagraph, li.MsoListParagraph, div.MsoListParagraph
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
p.MsoListParagraphCxSpFirst, li.MsoListParagraphCxSpFirst, div.MsoListParagraphCxSpFirst
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
p.MsoListParagraphCxSpMiddle, li.MsoListParagraphCxSpMiddle, div.MsoListParagraphCxSpMiddle
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:.5in;
	margin-bottom:.0001pt;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
p.MsoListParagraphCxSpLast, li.MsoListParagraphCxSpLast, div.MsoListParagraphCxSpLast
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:8.0pt;
	margin-left:.5in;
	line-height:107%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
span.UnresolvedMention
	{mso-style-name:"Unresolved Mention";
	color:gray;
	background:#E6E6E6;}
.MsoPapDefault
	{margin-bottom:8.0pt;
	line-height:107%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:2.0in 2.0in 2.0in 2.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link="#0563C1" vlink="#954F72">

<div class=WordSection1>

<p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:150%;
text-autospace:none'><b><span style='font-size:17.0pt;line-height:150%;
font-family:URWPalladioL-Bold'>Alzheimer’s Disease and Cognitive Impairment
Prediction</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:150%;
text-autospace:none'><b><span style='font-size:17.0pt;line-height:150%;
font-family:URWPalladioL-Bold'>CSCI E-109a Introduction to Data Science</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:150%;
text-autospace:none'><b><span style='font-size:17.0pt;line-height:150%;
font-family:URWPalladioL-Bold'>Xinyu Li</span></b></p>

<p class=MsoNormal align=center style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:0in;text-align:center;line-height:150%;
text-autospace:none'><b><span style='font-family:"Times New Roman","serif"'>&nbsp;</span></b></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><b><span
style='font-family:"Times New Roman","serif"'>Background:</span></b><span
style='font-family:"Times New Roman","serif"'> </span><span style='font-family:
URWPalladioL-Roma'>Alzheimer’s disease (AD) is a type of dementia that causes
problems with memory, thinking and behavior. AD is an irreversible process that
typically begins after age 60. Once a patient has been diagnosed, their mental
function usually declines until death. While some drug and non-drug treatments
may help with both the cognitive and behavioral symptoms, currently Alzheimer’s
disease has no cure.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>The personal, social, and economic impact
of AD is profound. In the United States, more than 5 million people aged 65 and
over su</span><span style='font-family:Rpxr'>ff</span><span style='font-family:
URWPalladioL-Roma'>er from the disease. AD is currently ranked as the sixth</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>leading cause of death in the United
States, and is the third leading cause of death for older people, just behind
heart disease and cancer (NIA, 2017). The estimated national cost of patient
care for Alzheimer’s and other types of dementia was $236 billion in 2016.
Therefore there is both a human and economic incentive to find an effective
therapy for AD.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>While scientists are still uncertain
about the precise cause of AD, research has identified strong indicators for
the disease. For example, an accumulation in the brain of Amyloid Beta protein</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>(also referred to as A</span><span
style='font-family:Rpxmi'>_ </span><span style='font-family:URWPalladioL-Roma'>protein
or amyloid plaque) that is dense enough to meet a certain threshold (i.e.,
Amyloid Beta positivity) has been identified as a risk factor for AD (Dana,
2014). Leading</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>biotechnology companies proactively
developing therapies for Alzheimer’s patients. Due to the currently
irreversible nature of AD, it is believed that the e</span><span
style='font-family:Rpxr'>ff</span><span style='font-family:URWPalladioL-Roma'>ectiveness
of any potential therapy greatly depends on early detection and treatment.</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;text-indent:-.25in;line-height:150%;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>1.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><b><span
style='font-family:"Times New Roman","serif"'>Problem Statement and Motivation:
</span></b><span style='font-family:"Times New Roman","serif"'>This should be
brief and self-contained:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Project goal: </span><span
style='font-family:URWPalladioL-Roma'>The goal for this project is to propose,
build and evaluate a data-driven model for a Alzheimer’s or cognitive
impairment related investigation using patient demographic information,</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>medical records, and related data. A
classic investigation would be centered around building a machine learning
solution for evaluating a patient’s risk of developing Alzheimer’s based on medical
history. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>With following issue addressed or should
be addressed:</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>Limited patient data available</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>Data is collected according to multiple protocols
(ADNI, ADNI GO, ADNI 2)</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>Some of the data has longitudinal
component that adds complexity</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>Labeling is not always reliable, e.g., it
might be not clear whether it’s AD or other form of dementia</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:URWPalladioL-Roma'>Early detection is key so find the
smallest and least expensive feature subset is important</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;text-indent:-.25in;line-height:150%;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>2.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><b><span
style='font-family:"Times New Roman","serif"'>Introduction and Description of
Data: </span></b><span style='font-family:"Times New Roman","serif"'>Description
of relevant knowledge. Why is this problem important? Why is it challenging?
Introduce the motivations for the project question and <span style='background:
yellow'>how that question was defined through preliminary EDA</span>.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>More
specifically, Biomarker data is the focus of these project. Longitudinal nature
of the data is considered and emphasis is more on data preprocessing. Based on
the nature of this problem, several multi-classification model is evaluated in
order to identify the model with good performance and identify the predictors
that are most effective predictors with respective to this problem with given
data set. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Two dataset
were considered: ADNIMERGE.csv and BIOMARK.csv; ADNIMERGE.csv is the main
dataset, and step by step when refine data pre-processing part, at final stage,
BIOMARK.csv is used. BIOMARKER predictors were selected in a way that still
could get valid dataset after join with ADNIMERG.csv in order to perform model
evaluation. Dataset has following issue or characteristics: </span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Limited
patient data available, especially after removing rows with missing data</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Data is collected according to multiple
protocols (ADNI, ADNI GO, ADNI2), there is ADNI 3, but only have less than 300
records, not enough to build credible model, so didn’t be part of the analysis
in this project.</span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Some of the data has longitudinal
components: one patient could have multiple visit with multiple records
(entry), some information is fixed, for example, demographic, like gender,
education, ethic, race, etc. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Because one of the major work is
data preprocessing, this will impact all the following step/results: model
building/evaluation etc. So each step, have its own modeling and results to corresponding
to its own data pre-processing. </span></p>

<p class=MsoNormal style='margin-top:0in;margin-right:0in;margin-bottom:0in;
margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Data pre-processing approach:</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Step
1. One participant could have multiple entry, DX is the diagnosis results, and
could change over time for one patient.  There are longitudinal data issue, to
solve this, DX_last is created to keep track one participant’s last available
diagnosis results.  DX_last is the response variable</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Step
2: based on step 1, DX_change is created to keep track if a participant’s
diagnosis results changes over time. If it is positive, the participant’s
records will be dropped from dataset. DX_last is the response variable</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Step
3: based on step 2predictors from BIOMARK.csv are selected, then join with
ADNIMERGE.csv based on participant ID, exam date, and protocol.  </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>            Step
3 also break into two part: CSF biomark were tested and Plasma biomark were
also tested.</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>Below are
scatter plot of top pick BIOMARK predictors that illustrate a clear boundary
between each region. </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>            </span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><a href="scatterPlot_DX_change_nobfill_joinADNI_CSF.JPG"><span
style='color:windowtext;text-decoration:none'><img border=0 width=690
height=344 id="Picture 1" src="Project%20Milestone4_files/image001.png"></span></a></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><a
href="scatterPlot_RVAL_DX_change_nobfill_joinADNI_CSF.JPG"><span
style='color:windowtext;text-decoration:none'><img border=0 width=641
height=393 id="Picture 2" src="Project%20Milestone4_files/image002.png"></span></a></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpMiddle style='margin-top:0in;margin-right:0in;
margin-bottom:0in;margin-left:1.0in;margin-bottom:.0001pt;line-height:normal;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;text-indent:-.25in;line-height:150%;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>3.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><b><span
style='font-family:"Times New Roman","serif"'>Literature Review</span></b><span
style='font-family:"Times New Roman","serif"'>/<b>Related Work: </b>This could
include noting any key papers, texts, or websites that you have used to develop
your modeling approach, as well as what others have</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>done on this problem in the past.
You must properly credit sources.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative">Alzheimer's
Disease Neuroimaging Initiative</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative">https://en.wikipedia.org/wiki/Alzheimer%27s_Disease_Neuroimaging_Initiative</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://www.nia.nih.gov/alzheimers/clinical-trials/alzheimers-disease-neuroimaging-initiative-2-adni2">Alzheimer's
Disease Neuroimaging Initiative 2 (ADNI2)</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://www.nia.nih.gov/alzheimers/clinical-trials/alzheimers-disease-neuroimaging-initiative-2-adni2">https://www.nia.nih.gov/alzheimers/clinical-trials/alzheimers-disease-neuroimaging-initiative-2-adni2</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-size:10.0pt;line-height:150%;font-family:"Times New Roman","serif";
color:#484A4C'><a
href="http://adni.loni.usc.edu/wp-content/uploads/2012/10/ADNI3-Procedures-Manual_v3.0_20170627.pdf">ADNI3
Procedures Manual Version 3.0</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="http://adni.loni.usc.edu/wp-content/uploads/2012/10/ADNI3-Procedures-Manual_v3.0_20170627.pdf"
target="_blank"><span style='font-size:10.0pt;line-height:150%'>http://adni.loni.usc.edu/wp-content/uploads/2012/10/ADNI3-Procedures-Manual_v3.0_20170627.pdf</span></a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-2-26">Neuronal
injury biomarkers and prognosis in ADNI subjects with normal cognition</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="https://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-2-26">https://actaneurocomms.biomedcentral.com/articles/10.1186/2051-5960-2-26</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="http://adni.loni.usc.edu/data-dictionary-search/?q=dx_bl">ADNI Data
Dictionary Search</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'><a
href="http://adni.loni.usc.edu/data-dictionary-search/?q=dx_bl">http://adni.loni.usc.edu/data-dictionary-search/?q=dx_bl</a></span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraphCxSpFirst style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;text-indent:-.25in;line-height:150%;
text-autospace:none'><span style='font-family:"Times New Roman","serif"'>4.<span
style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </span></span><b><span
style='font-family:"Times New Roman","serif"'>Modeling Approach and Project
Trajectory: </span></b><span style='font-family:"Times New Roman","serif"'>Include
</span></p>

<p class=MsoListParagraphCxSpLast style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>1) a baseline model for
comparison and</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>            Logistic regression
model, parameter tuned by cross validation</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoListParagraph style='margin-top:6.0pt;margin-right:11.0pt;
margin-bottom:6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>2) a description of your
implementations beyond the baseline model, parameter is tuned by cross
validation. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>multinomial logistic regression</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>one-vs-rest (OvR) logistic
regression</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>LDA, </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>QDA</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>KNN with k tuned by cross
validation</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Decision tree with tree depth by
running through train and test, and pick the depth that give best test accuracy
results. The best depth also validated by cross validation.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>Briefly summarize any changes in
your project goals or implementation plans you have made along the way. These changes
are a natural part of any project, even those that seem the most
straightforward at the beginning. The story you tell about how you arrived at
your results can powerfully illustrate your process.</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%;text-autospace:none'><span
style='font-family:"Times New Roman","serif"'>5. <b>Results, Conclusions, and
FutureWork: </b>Show and interpret your results. Summarize your results, the
strengths and short-comings of your results, and speculate on how you might address
these short-comings if given more time. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>Results:
significant predictors: </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>Best
performing model: decision tree</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>&nbsp;</span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>Conclusion:
including biomark information in the model help the model performance. </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>Future
work: imput the missing variable, </span></p>

<p class=MsoNormal style='margin-top:6.0pt;margin-right:11.0pt;margin-bottom:
6.0pt;margin-left:1.0in;line-height:150%'><span style='font-family:"Times New Roman","serif"'>Unsuccessful
trials: input CSF biomark variable backwark, not conceptually correct. Impact
on prediction power, marginal. </span></p>

</div>

</body>

</html>
